Skip to content

Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

Genetic Associations of Ocular Cancers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06725173
Enrollment
100
Registered
2024-12-10
Start date
2026-03-16
Completion date
2031-01-01
Last updated
2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma, Retinoblastoma Bilateral, Retinoblastoma, Extraocular, Retinoblastoma, Recurrent, Retinoblastoma Unilateral

Keywords

retinoblastoma, parent-of-origin

Brief summary

The goal of this observational study is undertake a detailed phenotypic and genotypic study of patients with ocular and secondary cancers due to mutations in the RB1 gene. Our research sequencing approach will allow advanced insight to for further detailed genotypic understanding of parent-of-origin for valuable insight into the genotype-phenotype relationship of this cancer syndrome.

Interventions

GENETICTargeted Long-read sequencing

All patient's will undergo targeted long-read sequencing to resolve genomic and epigenomic signatures of the RB1 gene

Sponsors

University of Washington
Lead SponsorOTHER
National Eye Institute (NEI)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients with molecularly proven retinoblastoma due to RB1 or a typical clinical retinoblastoma phenotype with genetic screening pending. * Able to give consent/parent or guardian able to give consent.

Exclusion criteria

* Patients unable or unwilling to undertake consent or clinical testing. * Patients unwilling to donate a saliva or blood sample in order to establish the genetic cause of their condition.

Design outcomes

Primary

MeasureTime frameDescription
Epigenomic and genomic profiling of the RB1 gene5 yearsMethylation signatures and genomic variant information to determine phase of the pathogenic variants in RB1 to specific differentially methylated signals in RB1

Countries

United States

Contacts

CONTACTDebarshi Mustafi, MD PhD
debarshi@uw.edu206-683-6305
PRINCIPAL_INVESTIGATORDebarshi Mustafi, MD PhD

University of Washington

PRINCIPAL_INVESTIGATORAndrew W Stacey, MD

University of Washington

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026